

HECHO RELEVANTE AB-BIOTICS, S.A.

06 de Junio de 2014

En cumplimiento de lo dispuesto en la Circular 9/2010 del Mercado Alternativo Bursátil y para su puesta a disposición del público como hecho relevante, por medio de la presente se pone a disposición del mercado la siguiente información relativa a AB-BIOTICS, S.A.:

La compañía ha participado en el 10º Foro MEDCAP de empresas de mediana capitalización, organizado por Bolsas y Mercados Españoles los días 27 y 28 de mayo de 2014.

Adjuntamos la presentación corporativa utilizada en dicho foro.

Quedamos a su disposición para cuantas aclaraciones consideren oportunas.

Atentamente,

En Barcelona, 06 de Junio de 2014.

AB-BIOTICS, S.A.

Sergi Audivert Brugué

Miquel Àngel Bonachera Sierra



Company Presentation 2014

Esta presentación ha sido utilizada como soporte en el Discovery Meeting del Foro MEDCAP 2014 organizado por BME. La lectura esquemática de la presente puede llevar al inversor a confusiones, **en ningún caso la información presentada substituye ninguno de los datos e informaciones publicados en el Plan de Negocio de AB-BIOTICS para el período 2014-2016 publicado en hecho relevante de día 22 de Mayo de 2014** y que puede ser descargado en el link: http://www.ab-biotics.com/biblioteca/arxius//plan_negocio_abr2014_16.pdf

Mission

AB-BIOTICS strives to improve health by developing products and providing services that help support healthy living and prevent disease.

Vision

AB-BIOTICS aspires to set a standard in the European biotechnology industry for both value and profitability.

History

2004

- Company Founded at Universitat Autònoma Barcelona



2008

- 1st Financing Round: Business Angels – €1 M



2011

- Capital Increase – €4,3M
- Acquisition of Quantum Experimental
- €6,2M Turnover



2010

- Financing Round: Public Trading €3,5M
- €3,6M Turnover



2012

- Capital Round - €4,3M
- International Expansion (US, BR)



Key Figures

AB-Biotics	2014
Patents fillings	113
R&D Exp. As % of Rev	29%
Total Employees (FTE)*	32
Of witch PhD Scientists	21
Of witch Business Develop.(FTE)	6
International licenses	20 markets
Market Cap. (ABB:MC)*	23 Million€

* This may vary within the year. Board members are not included.

**on date may 28th 2014

Locations

Girona:


Office and laboratory at Science Park of Universitat de Girona. Authorized genetic laboratory of 50m², and capable of processing more than 20,000 samples/yr.



Barcelona:

Company Headquarters at Universitat Autònoma Barcelona Research Park.

Shareholders



Total N° of Shares:
9.596.172

Total acciones	*End of 2013	9.596.172
Accionista	Nº acciones	% CS
Miquel À. Bonachera Sierra	1.271.993	13,26%
Sergi Audibert Brugué	1.271.993	13,26%
Luis Sánchez- La fuente Mariol	1.008.229	10,51%
Almirall	480.362	5,01%
Seed Capital	500.000	5,21%
Instituto Catalán de finanzas	372.093	3,88%



Balanced value of both value of both areas.
Balanced cash needs of both areas.

Probiotics Ready to Market

Probiotic	Dosage Form	IP	From:	Clinical Trial
AB-LIFE	Capsules	Yes	2011	Published*
AB-DENTIS	Tablets	Yes	2012	2 Ongoing
AB-LIFE PLUS	Capsules+ ALA	Yes	2013	Original
I31 (IBS)	Capsules	Yes	2013	Finished*
AB-DENTIS	Syringe	Yes	2013	Original
AB-INMUNO	Capsules (+Vit)	Not	2013	Published*
AB-COLIC	Drops	Yes	2014	Finished*
AB-LIFE FORT	Capsules+RYR	Yes	2014	Orig + Ongoing
AB-INTIMUS	Med. Device	Yes	2014	Finished*
AB-CISTITIS	Capsules	Yes	2014	Ongoing
AB-DENTIS	Chewing Gum	Yes	2014	Original
AB-COLIC	Monodoses	Yes	2014	Original


Other Solutions Ready to Market

Non-Probiotic	Indication / Form:	IP	From:	Clinical Trial
AB-FORTIS	API (Microencapsulated Iron)	Yes	2010	Published*
Neuropharmagen	CNS Pharmacogenetics	Yes	2011	Finished*
NFG Depression	MDD Pharmacogenetics	Yes	2012	Original
NFG ADHD	ADHD Pharmacogenetics	Not	2012	Ongoing
NFG Epilepsy	Epilepsy Pharmacogenet.	Not	2012	Ongoing
IronLac (AB-FOR)	Brest Feed Formula Caps	Yes	2014	Not
IronGest (AB-FOR)	Pregnant W. Formula Caps	Yes	2014	Not
IronKid (AB-FOR)	Children Cognitive dev. Liquid	Yes	2014	Ongoing



AB-BIOTICS AB-FUNCTIONAL INGREDIENTS - AB-LIFE


The Market



Cardiovascular disease is the world's **leading cause of death** (49% in Spain).* High cholesterol increases risk of cardiovascular disease.

Current treatments only target one of the two types of cholesterol (endogenous, dietary). Additionally, adverse hepatic and intestinal reactions arise at high doses.

WORLD LEADING CAUSES OF MORTALITY



Death causes in the world
(World Health Organization: Cardiovascular disease profile, 2005).


The Product



AB-LIFE, a **probiotic**, significantly **lowers both types** of cholesterol and has no adverse reactions at high doses. It can be delivered as food ingredient or supplement.

Patented product which entered **national phase** in June 2012 in 32 major economies.

CARDIOVASCULAR DISEASE RISK FACTORS
(Smoking, Hypertension, Systolic Blood Pressure)



Kannel WB, MC Gee D, Gordon T. A general cardiovascular risk profile. The Framingham study.

Recent News

Recent **license agreements** have been reached in Brazil, Spain, Mexico, USA, South Korea, Venezuela, and Eastern Europe. Many additional licenses are under negotiation.

Play
Movie



•Source: WHO 2010

**<http://www.youtube.com/user/ABBIOTICS#p/a/u/2/fv3IMsqv19o>

*** <http://www.youtube.com/user/ABBIOTICS#p/a/u/1/kkvjSCbA0X8>

En ningún caso la información presentada substituye ninguno de los datos e informaciones publicados en el Plan de Negocio de AB-BIOTICS para el período 2014-2016 publicado en hecho relevante de día 22 de Mayo de 2014




AB-FUNCTIONAL INGREDIENTS – IBS - 3.1

The Market



IBS, characterized by abdominal pain, discomfort, bloating and altered intestinal motility and transit, and affects between **10 - 15% of the population***.

Existing treatments are extremely limited by effect and carry significant side effects. Pharmacological treatment is limited in most countries.




The Product



IBS 3.1, a probiotic, achieves a **global improvement** in Quality of Life of afflicted patients, according to initial results from a multicentric clinical trial.

Patented product in national phase of IP protection, entering national phase in April 2012.



Recent News

First in class results from concluded clinical trials, with **best efficacy** of any IBS treatment.

Play
Movie



* Source: Quigley EM et al, July 2006 *Aliment. Pharmacol. Ther* ** http://www.youtube.com/user/ABBIOTICS#p/a/u/0/U4Gt2X_rpos



AB-BIOTICS


AB-FUNCTIONAL INGREDIENTS - AB-COLIC

The Market



- Inconsolable crying during at least 1 hour per day
- in 3 or more episodes
- during at least 1 week previously ruling out an organic etiology, like intestinal intussusception or others*

Probiotics are the best alternative for infant colic relief due to the ability to displace bacterial pathogens, the induction of IL-10 production and the absence of gas production.




The Product



The consumption of AB-COLIC during only 14 days by colicky infants (n=21) reduces the excessive crying in **67,5 %** in **subjects** with a **daily crying** duration between **60 and 240 minutes** without adverse effects.

Patented product, will enter in national phases within 2014.



Recent News

Clinical results and new definition of colic are going to be published in peer-reviewed clinical journals during 2014.

*Cuñé et al. 2014


En ningún caso la información presentada substituye ninguno de los datos e informaciones publicados en el Plan de Negocio de AB-BIOTICS para el período 2014-2016 publicado en hecho relevante de día 22 de Mayo de 2014



AB-BIOTICS


AB-FUNCTIONAL INGREDIENTS - AB-DENTALAC

The Market



Some factors (inadequate oral hygiene, illness, stress, poor diets...) can disrupt the protective oral balance of microbiota and allow bad bacteria to cause poor gum health, plaque buildup and bad breath.

90% of the population will suffer of gingivitis at some point of their life. 50%-70% of women develop gingivitis during their pregnancy. 50% of the population suffers from halitosis to some extent. Caries affects 60- 90% of schoolchildren and the vast majority of adults according to World Health Organization




The Product

AB:Dentalac®
THE ORAL HEALTH CARE

AB-DENTALAC is a patented probiotic formula for the global oral health. It has bactericidal activity against the most common oral pathogens, yet without producing significant amounts of acids, thus preserving the teeth.

Patented product, registered in Europe as a **Food Supplement** and is **ready to market**



Recent News

Paper published in **Archives of Oral Biology** characterization of strains suitable for the biofunctionality in oral health.*



AB-BIOTICS

AB-FUNCTIONAL INGREDIENTS - AB-INTIMUS

The Market



Vaginitis (inflammation of the vagina) is the most common gynecologic condition.

The most common causes of vaginitis in symptomatic women are bacterial vaginosis (40-45%), vaginal candidiasis (20-25%), and trichomoniasis (15-20%); yet 7-72% of women with vaginitis may remain undiagnosed.




The Product

AB-INTIMUS

The product is aimed at restoring the vaginal ecosystem to prevent and treat vaginal recurrent infections and/or resistant to antifungal treatments.

AB-INTIMUS is a **patent-pending probiotic product** designed to fight not only *Candida albicans*, but also *Candida glabrata* and can be co-administered with antifungals



Recent News

Clinical trial to be completed in Q12014 and product release in Spain expected for 2014.



AB-BIOTICS AB-FUNCTIONAL INGREDIENTS - AB-FORTIS


The Market



Iron deficiency in children, whether due to diet or absorption, can lead to lower infection resistance and **impaired psychomotor and cognitive development***.

Current fortification solutions have issues with iron oxidation, leading to a **false metallic taste** and lower shelf-life stability.

Population coverage (%) worldwide by anemia (WHO 2008)



*SAC = School-Age-Children


The Product

AB-FORTIS®

Encapsulated iron

AB-FORTIS can deliver **100% of the iron CDR** with **no oxidation** in yoghurt, milk, or meat, and can be delivered as a **food supplement**.

Patented product entering **national phase** of IP protection.
11 health claims approved by **EFSA**.



Recent News

Marketing forecasts are being prepared by **leading food companies** for launch in **2013**.

Spanish **

English ***

* Source: Kigangou, 2005, Ped. Res. 731

** <http://www.youtube.com/user/ABBIOTICS#p/a/u/0/wUx0Y1yDLxI>




*** <http://www.youtube.com/user/ABBIOTICS#p/a/u/1/aQHRX7Lt1A8>

Personalized Medicine and Pharmacogenetics

“It is not the analysis of disease genetic risk factors that shoes the most immediate promise for human health, but the application of genetic information to permit safer and more efficacious use of drugs.” – Caplan A., What Will Drive Genomics Over the Next 10 Years, Science 2011

“The evolution of personalized medicine will change the healthcare industry. In the process, it is likely that several “gamechangers” will emerge—aspects of new technology that will result in significant commercial or social impacts.” - DC-based research and consulting firm Social Technologies

“Industry consensus is that pharmacogenomics – that is, combination diagnostic and pharmaceutical products – will be part of mainstream medicine within 10 years.” - PWC



Neuropsychiatry

Neurofarmagen product launched since January 2010.

	% Prevalence	% Inefficient Treatment
Depression	10%	80%
Epilepsy, Schizophrenia, Bipolar	1%	20-30%

Cancer

Oncofarmagen pipeline product..

Drug response

It analyses the probability of a positive or negative response to the drug according to a patient's genetic profile.

Risk of adverse effects

It indicates a patient's probability of developing any of the adverse effects associated with the analysed drugs.

Dose

It provides information about the genetic factors that control drug metabolism to assess the most suitable dose.



Drugs analyzed: 47 active ingredients
Medical application: Patients that suffer from bipolar disorder or schizophrenia and/or depression.

Antidepressants		
Amitriptyline*	Bupropion	Citalopram
Clomipramine	Desipramine*	Doxepine
Duloxetine	Escitalopram	Fluoxetine
Fluvoxamine*	Imipramine*	Mianserin
Mirtazapine	Nortriptyline*	Paroxetine
Sertraline	Trimipramine*	Venlafaxine
Antipsychotics		
Aripiprazole*	Clozapine*	Haloperidol
Lithium	Olanzapine	Perphenazine*
Quetiapine	Risperidone	Thioridazine
Ziprasidone	Zuclopenthixol	
Stabilizers and anticonvulsants		
Valproic Acid	Carbamazepine	Clobazam
Clonazepam	Phenytoin	Phenobarbital
Lamotrigine	Levetiracetam	Lorazepam
Oxcarbazepine	Pregabalin	Topiramate
Vigabatrin		
Others		
Atomoxetine*	Methadone	Naloxone
Naltrexone	Pramipexole	



Drugs analyzed: 25 active ingredients
Medical application: Patients with depression and related symptoms of anxiety.


Antidepressants		
Amitriptyline*	Bupropion	Citalopram
Clomipramine	Desipramine*	Doxepine
Duloxetine	Escitalopram	Fluoxetine
Fluvoxamine*	Imipramine*	Mianserin
Mirtazapine	Nortriptyline*	Paroxetine
Sertraline	Trimipramine*	Venlafaxine
Antipsychotics		
Aripiprazole*	Olanzapine	Quetiapine
Risperidone		
Stabilizers and anticonvulsants		
Clobazam	Clonazepam	Lorazepam



Drugs analyzed: 13 active ingrednt.
Medical application: Patients with epilepsy and/or West syndrome.

Stabilizers and anticonvulsants		
Valproic Acid	Carbamazepine	Clobazam
Clonazepam	Phenytoin	Phenobarbital
Lamotrigine	Levetiracetam	Lorazepam
Oxcarbazepine	Pregabalin	Topiramate
Vigabatrin		

*Drugs approved by the FDA with pharmacogenetic information important to prescription.
<http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm>



AB-BIOTICS Team thank you!

